Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In APPY @ 1.72 for 1K....
Exited SONS @ 1.44 from 1.34 entry. Exited LGND @ 1.56 from 1.35 entry. I think both were called by professor $heff. Many thanks...Up on CENX, BWHI...Down on CCYC, GKK, UCBH, XTXI,TGB (but holding and hoping)...Go Wealth University.....Aggie...
Many thanks...I learned something today...Date of record is 02/09/2009...Ex-date is 2 days previous which would be 02/05...Thanks...Aggie...
Yes, I say that. But I have also read this....Aggie...
Crosstex Declares Quarterly Distribution and Dividend
5:06p ET January 29, 2009 (Business Wire)
The Crosstex Energy companies today announced the declaration of the quarterly distribution for Crosstex Energy, L.P. (NASDAQ: XTEX) (the Partnership) and the quarterly dividend for Crosstex Energy, Inc. (NASDAQ: XTXI) (the Corporation).
-- The quarterly distribution on the Partnership's common units will be $0.25 per unit. The distribution is payable February 13 to unitholders of record February 9.
-- The quarterly dividend on the Corporation's common stock will be $0.09 per share. The dividend is payable February 13 to shareholders of record February 9.
"These reduced distribution and dividend levels reflect our continued focus on executing our near-term business strategy, which emphasizes increasing liquidity and reducing leverage. This focus and the changes we've made will allow us to operate more efficiently and effectively during today's challenging commodity and financial markets," said Barry E. Davis, Crosstex Chairman, President and Chief Executive Officer. "Due to the continued decline in natural gas liquids prices and their impact on our processing business, as well as lower natural gas prices and their impact on producer drilling activity, we believe it is prudent to take steps to preserve value over the long term. We are actively exploring all alternatives to improve liquidity and to maintain our assets during this temporary dislocation in commodity and financial markets."
About the Crosstex Energy Companies
.09 divi for stockholders of record. I have seen the date as 02/05 and 02/09 so now sure exactly which is correct. Something to think about...Do your own dd...Aggie...
Ahhggg!!! I use Ameritrade and have not had the split reflected in the share count yet. Price, you betcha. I guess I cant sell until my account is up to date. Anyone else have the same problem.
Aggie....
LGND +.08 again today...Showing small green now...Aggie....
XRM +40%....Investors Update......
XERIUM TECHNOLOGIES ISSUES INVESTOR UPDATE
YOUNGSVILLE, N.C., February 2, 2009 – Xerium Technologies, Inc. (NYSE: XRM), a leading global manufacturer of clothing and roll covers used primarily in the paper production process, today issued the following update to shareholders from Stephen R. Light, President, Chief Executive Officer and Chairman:
My fellow shareholders,
It’s been several very busy months since I’ve had the opportunity to address the shareholders of our company and the people that follow our performance. I’d like to use this letter to you to bring you along on our journey, even though our 2008 results are not expected to be released until mid-March in conjunction with our 10K filing. As a consequence I’ll only comment on a few metrics that are indicative of what I consider to be an excellent first year in the Company’s turnaround.
While the politicians have nearly worn out the word “Change” in the Fall campaign, 2008 was a year of significant change for Xerium Technologies. During 2008 we radically changed the Company’s operating strategy, and changed the Chief Executive Officer, three division presidents, numerous senior managers, and three members of the Board of Directors retired and were replaced by industry experts. I believe the timing of our strategy change was appropriate as our credit amendment, which occurred about six months before the global credit crisis, provided us with extra impetus to find a competitive edge.
It is our strategy to reduce our financial leverage by generating cash in every manner possible and by applying this cash to debt reduction. This will be accomplished by improving the earnings we derive from our sales by removing all non-value adding work from our operations and processes and likewise using this increased cash flow to reduce debt. It is our strategy to develop new products that add clearly demonstrative value to our customers, and with these new products, earn their loyalty and enjoy improved pricing and market share. We also will invest modestly in products for markets that are parallel to ours where the barriers to entry are low and our technology and distribution processes make entry attractive. Finally, it is our strategy to maximize the contribution of every person in the organization to these efforts by removing performance barriers and developing incentives that serve to align their efforts with the first two strategies. We will have a smaller workforce of the best people, aligned to our strategies, and assigned to the tasks most appropriate to their skills and abilities.
Our new three element strategy has been communicated and embraced at every level and location of the Company. Early results of these strategies have already begun to show on our bottom line and the declining amount of our debt.
--------------------------------------------------------------------------------
Based upon preliminary unaudited results, our revenues and adjusted EBITDA both increased measurably in 2008 from 2007 in spite of deteriorating market conditions. We anticipate reporting 2008 revenues in the range of $620 to $640 million and “bank” adjusted EBITDA increased more than twelve percent compared to 2007. At year end, our balance sheet contained more than $25 million of cash after having made our loan payments on December 31, 2008.
Our preliminary results show we managed our Capex investment to between $36 and $42 million during the year, a substantial reduction from the $48 million invested in 2007 and reflects our new strategies. Much of the spending in 2008 was committed in late 2007 for the Asia Strategy and could not be cancelled. Consequently, in 2009 we expect to have ample Capex to serve our needs.
Our productivity initiatives have also delivered positive results in our measurement of sales per employee which increased more than 5.5% during 2008. This improvement does not recognize the recently announced shutdown of our Australian operations nor the curtailment of our Vietnam project. Both will result in more improvement. Workforce reductions are difficult but the health of the Company improves when the right number of people work on the right tasks. Plant closures and other personnel actions during 2008 reduced our workforce by nearly 100 people, with over 230 additional reductions to be implemented in the first quarter of 2009.
Our most public initiatives have dealt with our focus on reducing trade working capital to release cash “Trapped” on the balance sheet for debt repayment. We have been very successful. More than half of the cash we identified as “Trapped Cash” last March has been released. In the fourth quarter we concentrated on converting consignment inventories - inventories we own and store at a customer’s plant ready for their use - into cash. Good progress was made. Based on our preliminary fourth quarter results, our inventory turns increased from 3.2 turns in fiscal year 2007 to approximately 4.5 turns in fiscal year 2008. Our Days of Payables (DPO) exceeded our forty eight day goal and our receivables (DSO) approached their fifty day target as well. These gains released more than $40 million dollars which was used to fund voluntary debt payments and restructuring.
The effort expended by the four operating units to reach these levels uncovered many additional exciting opportunities they will harvest in 2009. One such opportunity is to reduce our lead time from receipt of an order to product shipment. Our sales personnel identified that in the challenged markets we find ourselves, lead time reduction, and its positive impact on reducing customer owned inventory, is a powerful competitive tool. As the year progressed, we noted a dramatic shift in customer behavior toward ordering more closely to the date they expected to need the product. While data we have from the Paper Clothing Association, a European based association of paper machine clothing manufacturers, indicates that overall clothing inventories in that market rose substantially throughout the year to nearly one billion dollars at current prices, our inventories in that market fell nearly twenty percent, as measured on an inventory turns basis. We believe this inventory build up occurred industry wide and partially accounts for the dramatic declines in new orders as the year drew to a close. Fortunately Xerium didn’t participate in this inventory buildup.
--------------------------------------------------------------------------------
A contributor to the improved revenue and EBITDA has been the Company’s position on establishing more appropriate pricing and inventory policies with its customers. As I joined the Company in February 2008, I was struck by what appeared to be an uneven distribution of value in the relationship between the customers and our company. We have worked hard on improving pricing and sales terms during the year to correct this situation and as our third quarter results demonstrated, we were able to slow the price decline to well below 2007 levels. Year to date through the third quarter we experienced less than 1.5% real price decline with an improving trend, a much lower level than in 2007. That trend continued into the fourth quarter. Competitive pressures will make increasing prices challenging. We believe the best solution to this problem is to be found through the introduction of new products.
In late 2008, we introduced the first continuous pressure sensing paper machine roll. This breakthrough product is SmartRoll™. SmartRoll™ enables the paper maker to maximize the performance of his entire process by knowing the operating pressures of the paper machine while the machine is running. Several of these SmartRoll™ systems are already in use. Market acceptance of this product has resulted in orders for most of our first quarter 2009 capacity in North America.
Without question, these are unprecedented economic times in the paper industry. While the deepening recession is impacting all of our customers, the fundamentals of the already transforming paper market continue to evolve. We are optimistic the end of the recession will bring strong demand for paper, pulp and board, but the long term fate of the newsprint segment is yet to be determined. Meanwhile, tissue, a segment in which we enjoy strong market share, is doing well with expanded production in 2008 in Europe and North America. We expect this trend to continue with acceleration in Asia as rising GDP brings increased tissue consumption over the long term.
As we enter 2009, we will wrestle with the economic climate we and everyone in our industry faces. We have set our revenue expectations accordingly and are confident in our plan. In 2009, Xerium will generate less revenue and lower “bank” adjusted EBITDA than in 2008. Our ability to reduce “bank” adjusted EBITDA in comparison to the revenue reduction is due to our much reduced cost structure. We made difficult decisions to make this possible. During 2009 we have implemented or announced the implementation of frozen wages, frozen U.S. pensions, eliminated the Company’s 401K matching program, eliminated retiree medical programs, curtailed spending, closed plants, high-graded our talent pool, and changed many of our historical suppliers to more competitive ones. Clearly we do not shy away from making tough decisions.
Our financial models show us in compliance with all of our loan restrictions and covenants throughout 2009. Of course, conditions may deteriorate beyond our assumptions, so there can be no guarantee our plan will be achieved, but I am confident now, knowing what I do about the markets and our 2009 plan, we have a realistic outlook about the markets and our capabilities to serve them. If our 2008 performance is indicative of our ability to conquer challenges, 2009 will be difficult, but we will finish the year in better shape than we entered. Over the past few weeks, we communicated this message to the agencies that rate our debt. We have previously announced that one agency has already increased our debt rating following their review of our progress in late 2008. We are hopeful the other agency will do the same as our results are sustained into 2009. If we are able to achieve this upgrade, we will receive a substantial reduction in our debt interest rate so that we may use the additional cash for incremental debt reduction.
--------------------------------------------------------------------------------
Adding to the our market challenges, the New York Stock Exchange notified the Company of our failure to comply with their listing standards in late December 2008. I believe a significant contributing factor to our stock price decline has been my desire to improve the operation of the business before I engaged analysts and investors in a dialogue about our plans. It is my belief that having meaningful results is better than having promises of future gains, so I made no promises other than my team would work hard on the right issues. But this meant little information other than quarterly filings made it to investor markets. I think the results I’ve shared with you here support the decision to be “silent”. Now that we have solid evidence of improvement, and as an element of our plan to regain NYSE listing standard compliance, we will actively engage the investment community and share with them the results of our first turnaround year. Xerium management will participate in investor conferences throughout 2009 to “spread the word” of the value inherent in our company and our progress to release that value. Public notice of our participation will be made as these are scheduled. In our work with the NYSE since receiving their notice, we learned that re-establishing our listing in good standing is a six to eighteen month process, even if our stock price rises quickly along with our market capitalization, to exceed compliance standard levels. We value this listing and will work diligently to preserve it.
As I write this letter to you, we are in our first quarter of 2009 and managing according to our plan. Our plan anticipates the first two quarters of 2009 to be the most challenging as customer inventories are adjusted downward with the consequence of soft ordering. As the inventory of finished paper is consumed, our customers’ mills will resume more normal production patterns. As their new orders arrive, our low finished goods inventory levels will enable us to resume production at our most efficient levels more quickly than our competitors. I believe that as the “channel” clears, a more stable but slightly lower revenue pattern will emerge. We have constructed our 2009 plan with this dynamic in mind.
This investor update has provided you with a brief look at our progress in 2008 and a sense of our 2009 planning. I look forward to discussing the details of our 2008 performance in our 10K filing and on our investor call in March.
Stephen R. Light
Chairman, President & CEO
About Xerium Technologies
Xerium Technologies, Inc. (NYSE: XRM) is a leading global manufacturer and supplier of two types of consumable products used primarily in the production of paper: clothing and roll covers. The Company, which operates around the world under a variety of brand names, utilizes a broad portfolio of patented and proprietary technologies to provide customers with tailored solutions and products integral to production, all designed to optimize performance and reduce operational costs. With 34 manufacturing facilities in 14 countries around the world, Xerium has approximately 3,600 employees.
--------------------------------------------------------------------------------
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. In some cases, forward-looking statements can be identified by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue” or the negative of these terms or other comparable terminology. Undue reliance should not be placed on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors that are, in some cases, beyond our control and that could materially affect actual results, levels of activity, performance, or achievements. Factors that could materially affect our actual results, levels of activity, performance or achievements include the following items: (i) our strategies and plans, including, but not limited to, those related to reducing financial leverage, developing new products, and reducing and realigning our workforce may be revised or may not be implemented as planned, and even if implemented, may not result in the expected benefits; (ii) our preliminary unaudited results may differ from our final audited results; (iii) the shutdown of our Australian operations and curtailment of our Vietnam project may not yield the expected improvements in our results; (iv) actual market conditions, including with respect to finished inventory levels, may be different from our expectations, market conditions may deteriorate beyond our assumptions, and competitive opportunities may not materialize as expected; (v) actions of debt rating agencies are beyond our control and may differ from our expectations; (vi) our plan to achieve compliance with NYSE continued listing standards may not be accepted by the NYSE; (vii) we may not meet the goals set forth in our plan to achieve NYSE compliance; (viii) even if we meet the goals set forth in the plan, we may not be able to achieve compliance with NYSE continued listing standards (ix) our revenues and profitability could be adversely affected by fluctuations in currency exchange rates; (x) our profitability would be reduced by a decline in the prices of our products; (xi) our profitability could be adversely affected by fluctuations in interest rates; (xii) we may not be able to develop and market new products successfully or we may not be successful in competing against new technologies developed by competitors; (xiii) changes in demand for our products, including our new products, such as SmartRoll™, could negatively impact our profitability; (xiv) our credit facility contains restrictive covenants, including covenants requiring compliance with minimum interest coverage and fixed charge coverage ratios and maximum leverage ratios, that will require us to improve our performance over time in order to comply therewith; (xv) we may have insufficient cash to fund growth and unexpected cash needs after satisfying our debt service obligations due to our high degree of leverage and significant debt service obligations; (xvi) we are subject to the risk of weaker economic conditions in the locations around the world where we conduct business, including without limitation the current turmoil in the credit markets and the impact of the current global economic crisis on the paper industry; (xvii) we may be required to incur significant costs to reorganize our operations in response to market changes in the paper industry; (xviii) we are subject to the risk of terrorist attacks or an outbreak or escalation of any insurrection or armed conflict involving the United States or any other country in which we conduct business, or any other national or international calamity; (xix) we are subject to any future changes in government regulation; (xx) we are subject to any changes in U.S. or foreign government policies, laws and practices regarding the repatriation of funds or taxes and (xxi) those
--------------------------------------------------------------------------------
other risks described under the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2008 filed with the Securities and Exchange Commission and subsequent SEC filings. If any of these risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary significantly from what we projected. Any forward-looking statement in this press release reflects our current views with respect to future events. We assume no obligation to publicly update or revise these forward-looking statements for any reason, whether as a result of new information, future events, or otherwise.
XRM up 40%
XRM up 35% today!
5.00/Share buyout announced.....
LGND - Closed HOD @ 2.38 +.26 +12.26%
LGND doing nicely today off of news.....
LGND ~
Monday, February 02 2009 9:05 AM, EST Ligand Announces Phase IIb Results With DARA Business Wire "US Press Releases "
SAN DIEGO --(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) (the "Company" or "Ligand") today announced positive preliminary results from the Phase IIb study for PS433540, the first-in-class Dual Acting Receptor Agonist (DARA) that targets the angiotensin and endothelin receptors.
The 261-patient, randomized, double-blind, placebo- and active-controlled study evaluated safety and efficacy at three different doses in subjects with Stage 1 and Stage 2 hypertension over 12 weeks of treatment. PS433540 was found to be safe and well tolerated and demonstrated statistically significant greater reductions in blood pressure than placebo. The high dose of PS433540 produced a statistically significantly greater reduction in blood pressure than the active comparator, irbesartan which was tested at its highest approved dose.
Summary of Phase IIb Trial Results
-- Patients were randomized to once-daily doses of PS433540 at 200 mg, 400 mg, or 800 mg doses, placebo, or irbesartan at a 300 mg dose for 12 weeks. -- PS433540 at 200 mg, 400 mg and 800 mg reduced systolic blood pressure by 13 mm Hg, 14 mm Hg, and 23 mm Hg, respectively. For diastolic blood pressure, the reductions with PS433540 were 7, 9, and 14 mm Hg respectively. All doses reduced blood pressure statistically significantly greater than placebo. -- The angiotensin receptor blocker (ARB) irbesartan reduced systolic blood pressure by 11 mm Hg and diastolic blood pressure by 7 mm Hg. The response to irbesartan was consistent with the published literature. -- The 800 mg daily dose of PS433540 produced a statistically significant reduction in systolic and diastolic blood pressure as compared to irbesartan. The other dose levels of PS433540 were not statistically significantly different from irbesartan. -- For PS433540, the percentages of patients who reached a blood pressure goal of less than 140/90 at 12-weeks were 36%, 52%, and 62% with the 200 mg, 400 mg and 800 mg doses, respectively; by comparison, 32% of irbesartan patients and 9% of placebo patients reached the goal for blood pressure control at the end of 12 weeks. The 800 mg dose of PS433540 showed a statistically significantly higher percentage of patients achieving blood pressure control compared to irbesartan. -- PS433540 was generally well tolerated and there were no serious adverse events associated with therapy. Headache was most frequent in the placebo group (17%), while edema was most frequent on the 800 mg dose (11%). Other adverse events occurred less frequently. One subject in the placebo group had liver function elevations greater than three times the upper limit of normal.
In previously completed Phase I clinical trials in normal subjects, PS433540 was well tolerated, demonstrated a pharmacokinetic profile consistent with once-daily oral administration, and fully blocked an increase in blood pressure in an angiotensin challenge test at either 250 mg or 500 mg dose levels.
In a previously completed Phase IIa clinical trial in hypertensive patients, PS433540 at either 200 mg or 500 mg once-daily produced a statistically significantly greater reduction in blood pressure compared to placebo. The drug was well tolerated by patients. Most of the adverse events reported were mild or moderate in severity and included headaches and minor musculoskeletal and respiratory complaints. There were no increases in liver enzymes above two times the upper limit of normal.
Plans for DARA
PS433540 (DARA) is a program Ligand acquired as part of its acquisition of Pharmacopeia in December 2008 . Given the drug's unique mechanism of action targeting the angiotensin and endothelin receptors, DARA has the potential for treating diabetic nephropathy. Going forward, Ligand plans to pursue discussions with potential collaborators to partner the program based on the data obtained up to this point. While Ligand is pleased with the outcome of this Phase IIb trial, there can be no assurance the Company will be able to secure a partnership for the program.
About Ligand Pharmaceuticals
Ligand discovers and develops new drugs that address critical unmet medical needs of patients with muscle wasting, frailty, hormone-related diseases, osteoporosis, inflammatory diseases and anemia. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties and reflect Ligand's judgment as of the date of this press release. These statements include those regarding data analysis and evaluation of PS433540, utility or potential benefits to patients, plans for continued development and further studies of PS433540 for the treatment of diseases associated with hypertension and diabetic nephropathy. Actual events or results may differ from our expectations. For example, there can be no assurance that other trials or evaluations of PS433540 will be favorable or that they will confirm results of previous studies, that data evaluation will be completed or demonstrate any hypothesis or endpoint, that PS433540 will provide utility or benefits to certain patients, that any presentations will be favorably received, that PS433540 will be useful as a single agent or in combination with other drugs, that marketing applications will be filed or, if filed, approved, or that clinical or commercial development of these product candidates will be initiated, completed or successful or that our rights to PS433540 will not be successfully challenged. Our stock price may suffer as a result of the failure of any trials to be completed or meet their endpoints or if any actual events differ from our expectations. Additional information concerning these and other risk factors affecting Ligand can be found in prior press releases as well as in public periodic filings with the Securities and Exchange Commission , available via
www.ligand.com. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this press release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Source: Ligand Pharmaceuticals Incorporated
$heff...I got some SONS Friday also @ 1.34 ...Gonna ride this one with you again...Paid off handsomely the last time you called it...Aggie...
TGB breaking out... .91 ...Aggie..
Very strange thing happened today. Every single one of my stocks closed green. I think today was the first day ever that I can say that. This board and all the resident experts are like a dream come true. I cannot thank everyone who contributes to the board enough.....Aggie...
Prof Chartinator,
Realisticly, what are your selling points for LZR and XTXI. I am in XTXI at 3.94 and LZR at 7.50. I dont have the oppurtunity to watch the market 24/7, so I rely on GTC sell orders to take profits when I can. I dont want to sell myself short on these two as I did with CRYP, but also want to be realistic. I know the answer is "it depends on.....", but where would you recommend targets on these securities for a novice trader who may only be able to check the market 2-3 times daily.
Great board with great people.
Aggie...
GLBL sold @ 3.45 from 3.29 entry. Picked up some XTXI @ 3.94....
Yeah...Figures the moment I am out at 1.35 it runs to 1.45...Not complaining though...Have a great day...Aggie...
PDGI out 1.36 (small gain)...In TGB .8301...Thanks Chart...
PDGI up 12% also...
SRZ up 12%
CRYP - Looks like my GTC sell hit today at 4.30 (from 3.70 entry)...Wish I had held longer, but will take what I got...Thanks Chart...Aggie...
What fueled the rise today???? Been away from my computer and am pleasantly suprised...TIA..AGGIE
I guess...When was the last time a share of this stock traded???Would certianly like to see a bit more liquidity...IMO..Aggie...
Time and Sales question. I notice many times that there are codes associated with AH sales. Just curious if someone could point me to some documentation as to what the coding represents...Example below...In this example the code is a 4, but I have seen t, f, etc....TIA...Aggie....
4 1.1903 100 NDD 16:14:10
4 1.1903 300 NDD 16:14:10
4 1.1903 800 NDD 16:14:09
4 1.1903 300 NDD 16:14:06
4 1.1903 400 NDD 16:13:50
4 1.1903 200 NDD 16:13:46
4 1.1903 600 NDD 16:13:36
4 1.1903 100 NDD 16:13:24
4 1.1903 400 NDD 16:12:51
4 1.1925 100 NDD 16:12:48
4 1.1903 100 NDD 16:12:47
4 1.1892 1000 NDD 16:11:56
4 1.1892 2600 NDD 16:11:53
Brutal day...Thank god for SONS...1.32 to 1.75 (Thank you $heff!!!)...Takes the sting out of losing my a@@ on my other positions...Hopefully, things turn around soon.....Aggie.....
GKK - Rocking after market....
t 1.40 650 NYE 17:06:00
t 1.39 250 NYE 17:06:00
t 1.32 100 NLS 16:02:04
t 1.32 500 NLS 16:02:04
t 1.32 500 NLS 16:02:04
f 1.25 200 NLS 16:02:02
f 1.25 300 NLS 16:02:02
f 1.25 100 NLS 16:02:00
t 1.25 400 NYE 16:02:00
t 1.25 300 NYE 16:02:00
t 1.25 500 NYE 16:01:59
t 1.25 300 NYE 16:01:59
1.48 19900 NYE 16:01:57
1.48 10600 NYE 16:01:55
1.22 200 NYE 15:59:56
1.23 100 NYE 15:59:46
1.24 600 NYE 15:59:27
1.23 200 NYE 15:59:24
Two large buys right at close....Trading as high as 1.32 in after market...Aggie..
1.48 19900 NYE 16:01:57
1.48 10600 NYE 16:01:55
1.22 200 NYE 15:59:56
1.23 100 NYE 15:59:46
1.24 600 NYE 15:59:27
1.23 200 NYE 15:59:24
1.23 100 NLS 15:59:24
1.22 300 NYE 15:59:19
1.22 100 NYE 15:59:19
f 1.23 100 NYE 15:58:58
1.25 100 NLS 15:58:56
1.25 100 NLS 15:58:56
1.24 100 NLS 15:58:56
1.24 100 NLS 15:58:56
1.24 200 NLS 15:58:56
1.24 200 NLS 15:58:56
1.23 800 NDD 15:58:51
1.23 100 NDD 15:58:43
1.22 100 NYE 15:58:34
PDGI up to 1.15 off low of 1.00
SRZ up to 1.25 off low of 1.04
GKK up to 1.20 off low of 1.03
XRM up to .67 off low of .58
CYCC up to .42 off low of .41
INVC up to .1162 off low of .10
All down big for the week, but starting to move back in the + direction....Aggie..
PLXT - Professors, your assessment please!...no debt...bounced off 52 week low today (1.45)...currently 1.58...Thanks...Aggie..
Professors...Could I get your assessment on NXG...Ascending wedge formation and late night news...PM is .95 ask...Thanks...Aggie...
http://www.newswire.ca/en/releases/archive/January2009/13/c7287.html
I know what you mean. I cant watch the market every minute either. But, I do enter GTC sell orders for about 10%-15%% profit and I got in and out of GKK without any problem. FWIW, got back in today at 1.25....Aggie...
Got back in GKK @ 1.25 and PDGI @ 1.28 for 2nd time...Aggie...
GKK was alerted on 1/7 @ 1.55...Ran as high as 1.75...I got out at 1.70...Also traded as high as 1.72 on 1/8...There was plenty of oppurtunity to take profits...
GKK was alerted on 1/7 @ 1.55...Ran as high as 1.75...I got out at 1.70...Also traded as high as 1.72 on 1/8...There was plenty of oppurtunity to take profits...
XRM - Appears to have traded as high as .92 after market on Friday (If I understand this correctly)....Aggie...
t 0.92 4080 NDD 16:35:10
t 0.82 3700 NYE 16:22:23
t 0.82 100 NYE 16:22:23
t 0.82 4800 NYE 16:22:10
t 0.82 100 NYE 16:22:10
t 0.82 100 NYE 16:22:10
t 0.82 9800 NYE 16:22:02
t 0.82 100 NYE 16:22:01
t 0.82 100 NYE 16:22:01
0.78 5600 NYE 16:03:52
0.79 2600 NYE 15:59:21
0.79 5366 NDD 15:59:21
0.79 100 NLS 15:59:21
0.77 300 NYE 15:59:17
0.78 500 NDD 15:59:11
0.78 600 NYE 15:59:11
My 2009 so far!!! My work does not allow me to follow the market every minute. Therefore, as soon as I buy a position, I put in a sell order so I can take some profits when they occur. Too many times I have been up one minute, checked again after the close and lost my a@@. Therefore, I am pretty quick on the sell button.
2009 to date..up roughly $2.5K:
ZLC: In $3.46 out $4.00
GPP: In $1.18 out $1.45
ICO: In $2.70/2.40 out $2.90
SRZ: In $1.58 out $1.90
CAR: in .77 out $1.05
AFFX: In 3.16 out $3.32
PDGI: In 1.16 out $1.40
My only down trade so far this year is NT which I stopped out @.25 today before the run.
I owe it all to Chart and the fine people here on this board. I am now a loyal follower.
Currently holding SRZ, CYCC, GKK, and XRM.
Many thanks....Aggie...
Got 9's, 5's and 3's...No more for me until news...Aggie...
PNTV - up 55% off your vidio chart...Amazing...Aggie..